The annual J.P. Morgan Healthcare Conference “is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community” (JPMorgan.com).
This year’s conference covered a wide range of trends in healthcare, from anticipated topics like drug pricing reform, to repeat themes with an unexpected twist (where’s all of the M&A activity?), and everything in between.
In case you missed it, we put together a summary of the top news headlines and best social media commentary capturing the biggest takeaways from JPM 2020.
Top Headlines
Drug Pricing
Big Pharma CEOs Weigh In On Drug Prices At JPM 2020: CNBC
Analysis: Pharma Executives Address Drug Prices At JPM 2020 As Political Pressure For Reform Builds: Barron’s
Drugmakers Exploring New Methods Of Payment For Expensive Medicines: Wall Street Journal
M&A Activity
Pharma Dealmaking Slows At This Year’s JP Morgan Healthcare Conference, Executives Say: FiercePharma
Lack Of Large Deals Seen As Top Theme At JP Morgan Healthcare Conference So Far: STAT
The Next Therapeutic Area of Major Innovation?
Neuroscience Field Poised For Drug Development Innovation, Karuna CEO Says: FierceBiotech
Roche Sees Growing Role For Neuroscience This Decade: BioPharma Dive
Digital Health
JPM 2020 Attendees Wary Of Vague “Digital Health” Definition, Address Drug Pricing: CNBC
Drug Launch Strategies
Novartis Executives Discuss Drug Launch Strategies: FiercePharma
Merck CEO Ken Frazier Highlights Keytruda Success, Drug Price Challenges, And More: Fox Business
Year of the Consumer
JPM’s Lisa Gill Says Conference Is Focused On The “Year Of The Consumer:” CNBC’s Mad Money
Social Media Commentary
1. @Chrissyfarr on her top 5 takeaways from #JPM20.
Collected some thoughts on the big takeaways and discussions from #JPM20 for those who aren’t here. Here are my top 5: https://t.co/gxhfFDasLm
— Christina Farr (@chrissyfarr) January 15, 2020
2. @jacqueline_says on the current status of digital health.
#jpm20: @chrissyfarr + @AmerMedicalAssn discuss evidence-based care. There are 300k #mhealth apps, 40k which are patient-facing. Out of the 150 deemed the “best”, most weren’t even usable, the AMA tells Chrissy. #JPMorgan2020 #JPM2020 #AI #DigitalHealth pic.twitter.com/hvqY2fqxuD
— Jacqueline DiChiara (@jacqueline_says) January 14, 2020
3. @AndyBiotech on the “lack of M&A at #JPM20.”
This is probably the most interesting stat in 2020 E&Y Firepower Report and explains the lack of M&A at #JPM20
"69% of surveyed dealmakers say the valuation gap between buyers and sellers is the largest its been since 2008"https://t.co/8zSBhWehTC pic.twitter.com/S2wypdgzG4
— Andy Biotech (@AndyBiotech) January 15, 2020
4. @MariaBartiromo on pharma research investments.
Today @Merck ceo ken Frazier on #cancer deaths ⬇️ while the co continues to invest in #Alzheimers research. @MorningsMaria @FoxBusiness pic.twitter.com/uYb7PVnCRI
— Maria Bartiromo (@MariaBartiromo) January 14, 2020
5. @Chrissyfarr on unanimous opinions about “health data interoperability.”
On my #JPM2020 panel with @AashimaTweets from Google, Ken Ehlert from UHG, @othman from Color, Salesforce's Jujhar Singh & Novartis' VP of BD, there was one thing everyone agreed on:
2020 is the year we will see some movement on health data interoperability.
Hope so!
— Christina Farr (@chrissyfarr) January 16, 2020
For more industry insights, sign up for Healthcare Marketing Daily, follow us on LinkedIn, and don’t forget to return to this space!
